摘要
目的 制定甲真菌病临床评分指数(SCIO),并观察其指导特比萘芬连续疗法治疗甲真菌病的疗效及安全性。方法 根据影响甲真菌病疗效的主要因素;甲真菌病的病情和甲的生长速度,制定SCIO。计算99例甲真菌病患者靶甲的SCIO积分,并予相应疗程的特比萘芬口服治疗。结果 94例患者,停药时(近期)临床痊愈率15.96％,有效率51.06％,真菌学治愈率72.34％;停药后3个月(中期)临床痊愈率79.79％,有效率91.49％,真菌学治愈率89.36％。不良反应发生率为16.16％。结论 SCIO具有一定的科学性和实用性,指导特比萘芬连续疗法治疗甲真菌病疗效良好。
Objective Formulate the scoring clinical index of onychomycosis (SCIO),to observe the efficacy and safe-
ty with SCIO guide the treatment of onychomycosis in terbinafine continuous therapy. Mathods Based on the main factors
of influence the efficacy of onychomycosis, the state of onychomycosis and the growth's speed of nail to formulate SCIO, to
calculate respectively the target nail's SCIO in 99 patients. The course of treatment was to take orally terbinafine one tablet
every day according as relevant period of terbinafine. Results In 94 patients, in the near future and metaphase, the cure rate
of onychomycosis were 15.96% and 79.79% respectively, the effective rate were 51.06% and 91.49% respectively, the
fungal infection clearance rates were 72.34% and 89.36% respectively. Conclusion SCIO is scientific and practical,which
guides the treatment of onychomycosis with terbinafine continuous therapy. It is effective and secure.
出处
《中国皮肤性病学杂志》
CAS
北大核心
2004年第7期406-409,共4页
The Chinese Journal of Dermatovenereology
